Skip to main content

JAZZ

Stock
Health Care
Biotechnology

Performance overview

JAZZ Price
Price Chart

Forward-looking statistics

Beta
0.55
Risk
27.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Company info

SectorHealth Care
IndustryBiotechnology
Employees3K
Market cap$7.1B

Fundamentals

Enterprise value$9.4B
Revenue$4.1B
Revenue per employee—
Profit margin11.86%
Debt to equity129.82

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$7.36
Dividend per share—
Revenue per share$66.15
Avg trading volume (30 day)$84M
Avg trading volume (10 day)$81M
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+2.7
Liquidity+0.4
Inflation-1.8
Commodities-0.1
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio5.08
Price to sales1.63
P/E Ratio5.08
Enterprise Value to Revenue2.31
Price to book1.62

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Is JAZZ Stock Undervalued At $110?

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with anticipated peak annual sales surpassing $2 billion.

Forbes (July 7, 2025)
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free